Literature DB >> 17047085

Comparative proteomic profiles of meningioma subtypes.

Hiroaki Okamoto1, Jie Li, Alexander O Vortmeyer, Howard Jaffe, Youn-Soo Lee, Sven Gläsker, Tae-Sung Sohn, Weifen Zeng, Barbara Ikejiri, Martin A Proescholdt, Christina Mayer, Robert J Weil, Edward H Oldfield, Zhengping Zhuang.   

Abstract

Meningiomas are classified into three groups (benign, atypical, and anaplastic) based on morphologic characteristics. Atypical meningiomas, which are WHO grade 2 tumors, and anaplastic meningiomas, which are WHO grade 3 tumors, exhibit an increased risk of recurrence and premature death compared with benign WHO grade 1 tumors. Although atypical and anaplastic meningiomas account for <10% of all of meningiomas, it can be difficult to distinguish them from benign meningiomas by morphologic criteria alone. We used selective tissue microdissection to examine 24 human meningiomas and did two-dimensional gel electrophoresis to determine protein expression patterns. Proteins expressed differentially by meningiomas of each WHO grade were identified and sequenced. Proteomic analysis revealed protein expression patterns unique to WHO grade 1, 2, and 3 meningiomas and identified 24 proteins that distinguish each subtype. Fifteen proteins showed significant changes in expression level between benign and atypical meningiomas, whereas nine distinguished atypical from anaplastic meningiomas. Differential protein expression was confirmed by Western blotting and immunohistochemistry. We established differential proteomic profiles that characterize and distinguish meningiomas of increasing grades. The proteins and proteomic profiles enhance understanding of the pathogenesis of meningiomas and have implications for diagnosis, prognosis, and treatment.

Entities:  

Mesh:

Year:  2006        PMID: 17047085     DOI: 10.1158/0008-5472.CAN-06-0955

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl.

Authors:  Jie Lu; Jeffrey Chiang; Rajiv R Iyer; Eli Thompson; Christine R Kaneski; David S Xu; Chunzhang Yang; Masako Chen; Richard J Hodes; Russell R Lonser; Roscoe O Brady; Zhengping Zhuang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-22       Impact factor: 11.205

2.  Comparative protein profiling reveals minichromosome maintenance (MCM) proteins as novel potential tumor markers for meningiomas.

Authors:  Okay Saydam; Ozlem Senol; Tieneke B M Schaaij-Visser; Thang V Pham; Sander R Piersma; Anat O Stemmer-Rachamimov; Thomas Wurdinger; Saskia M Peerdeman; Connie R Jimenez
Journal:  J Proteome Res       Date:  2010-01       Impact factor: 4.466

3.  Proteomic identification of glutamine synthetase as a differential marker for oligodendrogliomas and astrocytomas.

Authors:  Zhengping Zhuang; Meng Qi; Jie Li; Hiroaki Okamoto; David S Xu; Rajiv R Iyer; Jie Lu; Chunzhang Yang; Robert J Weil; Alexander Vortmeyer; Russell R Lonser
Journal:  J Neurosurg       Date:  2011-06-17       Impact factor: 5.115

4.  Proteomics Analysis of Brain Meningiomas in Pursuit of Novel Biomarkers of the Aggressive Behavior.

Authors:  Garni Barkhoudarian; Julian P Whitelegge; Daniel F Kelly; Margaret Simonian
Journal:  J Proteomics Bioinform       Date:  2016

5.  Comparative Proteomic Profiling Using Two-Dimensional Gel Electrophoresis and Identification via LC-MS/MS Reveals Novel Protein Biomarkers to Identify Aggressive Subtypes of WHO Grade I Meningioma.

Authors:  Joshua W Osbun; Philip D Tatman; Sumanpreet Kaur; Carolina Parada; Tina Busald; Luis Gonzalez-Cuyar; Min Shi; Donald E Born; Jing Zhang; Manuel Ferreira
Journal:  J Neurol Surg B Skull Base       Date:  2017-04-26

6.  Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia.

Authors:  Zhengping Zhuang; Chunzhang Yang; Felipe Lorenzo; Maria Merino; Tito Fojo; Electron Kebebew; Vera Popovic; Constantine A Stratakis; Josef T Prchal; Karel Pacak
Journal:  N Engl J Med       Date:  2012-09-06       Impact factor: 91.245

7.  Molecular and translational advances in meningiomas.

Authors:  Suganth Suppiah; Farshad Nassiri; Wenya Linda Bi; Ian F Dunn; Clemens Oliver Hanemann; Craig M Horbinski; Rintaro Hashizume; Charles David James; Christian Mawrin; Houtan Noushmehr; Arie Perry; Felix Sahm; Andrew Sloan; Andreas Von Deimling; Patrick Y Wen; Kenneth Aldape; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

Review 8.  Meningiomas and Proteomics: Focus on New Potential Biomarkers and Molecular Pathways.

Authors:  Rosaria Viola Abbritti; Francesca Polito; Maria Cucinotta; Claudio Lo Giudice; Maria Caffo; Chiara Tomasello; Antonino Germanò; Mohammed Aguennouz
Journal:  Cancer Genomics Proteomics       Date:  2016 09-10       Impact factor: 4.069

9.  Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype.

Authors:  Carl Wibom; Lina Mörén; Mads Aarhus; Per Morten Knappskog; Morten Lund-Johansen; Henrik Antti; A Tommy Bergenheim
Journal:  J Neurooncol       Date:  2009-04-07       Impact factor: 4.130

10.  Preoperative subtyping of meningiomas by perfusion MR imaging.

Authors:  Hao Zhang; Lars A Rödiger; Tianzhen Shen; Jingtao Miao; Matthijs Oudkerk
Journal:  Neuroradiology       Date:  2008-06-10       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.